Register for our free email digests:
Division of Amgen Inc.
Latest From Avidia Inc.
Once an unlikely scenario, corporate venture funds now are making up a larger and larger part of investment rounds for early-stage biotechs; these investments are buoyed by VCs launching their own firms. Plus news on recent financing activity from Avaxia Biologics, Clovis Oncology, Protagonist Therapeutics and Dermira.
AbbVie has been filling out its pipeline with small deals that could result in a follow-on drug to its blockbuster Humira; it’s most recent investment is in a small company doing further work in the space.
Alvine and AbbVie have inked a deal that could allow the larger company to acquire the biotech based on results of a Phase IIb trial for its celiac disease treatment.
Companies with large-molecule expertise increasingly are eyeing primary care markets, confident that improvements in safety and efficacy will make them competitive with oral standards of care.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- Amgen Inc.
- Senior Management
Peter Van Vlasellaer, PhD, CEO
Jose-Carlos Gutierrez-Ramos, PhD, SVP, Research & Non-Clinical Dev. & CSO
- Contact Info
Phone: (650) 404-2000
2450 Bayshore Pkwy.
Mountain View, CA 94043
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.